Biotech Values

[caravon]

"Median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76; p=0.0049).

Median progression-free survival (PFS) was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44; p<0.0001).

Objective response rates per RECIST 1.1 were 4 percent with cabozantinib and 0.4 percent with placebo (p=0.0086)."

It is interesting that PFS was increased by 3.3 months whether OS was increased by just 2.2 months.